New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:57 EDTCELGCelgene announced updated OS results from post-hoc analysis of Abraxane study
Celgene announced updated Overall Survival, OS, results from a post-hoc analysis of its phase III IMPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial, study of ABRAXANE, paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-na´ve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology, ASCO, annual meeting in Chicago, Ill. The analysis also showed that the treatment effect on OS for pre-specified subgroups analyzed in the trial remained consistent across patient subgroups. Specifically, patients with Karnofsky Performance Status, KPS, KPS 90-100 had a higher median OS on ABRAXANE plus gemcitabine as compared to gemcitabine alone [median OS 9.7 months vs. 7.9 months. Patients with KPS 70-80 also maintained a benefit [median OS 7.6 months vs. 4.3 months. This updated analysis also evaluated the prognostic effects of CA19-9 and neutrophil-to-lymphocyte ratio, NLR. Both elevated CA19-9 and elevated NLR were associated with poorer survival. Further, treatment with ABRAXANE plus gemcitabine appeared to reduce the effect of CA19-9 as a poor prognostic factor, as similar overall survival was observed regardless of CA19-9 level.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 7, 2015
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use